“Evidencias en Pediatría” (Evidences in Pediatrics) is a journal published only for health professionals. If you are not a health professional and you are visiting this site, you should know that the provided information can never replace the relationship between you and your doctor.
Privacy and data protection
The editorial board of the journal Evidencias en Pediatría (EP) takes very seriously the privacy of users’ data. Under no circumstances does it redistribute, sell, or make any kind of transfer of information obtained from visitors.
In accordance with the current legislation, if you have voluntarily submitted information to our site, you can use your right to modify it or cancel it by contacting the technical team of this website. Under the current legislation, the information form file, called “electronic table of contents” (e-TOC) has been declared to the Agencia de Protección de Datos (Spanish Agency for Data Protection) https://www.agpd.es/portalwebAGPD/index-ides-idphp.php
Links to external sites
This page may include links to other websites that might be of interest to users. This does not involve any property or responsibility of this journal site on the content of such links, neither on the updating or access conditions. However, these items are checked regularly by the Evidencias en Pediatría (EP) journal Editorial Board.
Linking from external sites
Linking to this website is permitted, and we promote and encourage it. There is no need of previous approval of any kind to link us. In all cases, the links should lead to a full display of the journal Evidencias en Pediatría website and never in other sites’ frames. The complete web address of the journal Evidencias en Pediatría (EP) has to appear always in the address toolbar. This could be a problem when linking to us from websites that use frames. In case that you have technical problems to achieve this, even when you are trying to link us out of any frame, please contact us.
Free Software mentioned in the site
The journal Evidencias en Pediatría (EP / Evidences in Pediatrics) includes occasional references to some kind of free software. Included links lead directly to the companies and organizations websites where this material is offered. The visitor accessing these links should carefully follow the instructions provided for each company to access their software. The journal EP Editorial Board is beyond any possible relationships generated between visitors and those entities. For any question please send an email using the mail form that we offer.
Rights of the author, editor and reader
The journal Evidencias en Pediatría does not demand from the authors the donation of their right on their manuscripts as a requisite to publish them. The relationship between the magazine and the authors will be regulated as it is described below.
The journal Evidencias en Pediatría (Evidences in Pediatrics) recognizes as inalienable the intellectual and moral rights of the authors concerning the content of their published manuscripts. Any use of these manuscripts must recognize this authorship in an explicit manner.
The journal Evidencias en Pediatría (EP / Evidences in Pediatrics) therefore, accepts that the authors could deposit, at institutional repositories or personal websites, an electronic copy of the revised and finally accepted version of the manuscript once it has been already published. This deposit will be done under the responsibility of the authors and specifically mention the original source (website of the journal Evidencías en Pediatría) where the original version can be found.
The property and rights of the published manuscripts, in its final format, are reserved to and are shared by the journal Evidencias en Pediatría (Evidences in Pediatrics) and the authors. The management of the manuscripts is left to the publisher as an exclusive competence.
However, as one of the goals of Evidencias en Pediatría (EP / Evidences in Pediatrics) is the maximum spread and circulation of its articles among the scientific and professional community, it is permitted to download (from the website: www.evidenciasenpediatria.es) and file a copy of them for individual and private use and without any financial gain. Any use outside these limits must have prior permission of the publisher. In some cases the copy and use may be abide by payment of economic rights that the publisher will manage in common with the authors, according to the publisher standards. In this case it could be formalized as a publishing rights management contract.
The publishing policy in relation to Evidencias en Pediatría web users (www.evidenciasenpediatria.es) assumes the terms of a Creative Commons ® license of Attribution-Non Commercial - No Derivative Works kind. (http://creativecommons.org/licenses/by-nc-nd/3.0/en/).
Evidencias en Pediatría (EP / Evidences in Pediatrics) is a publication of the “Asociación Española de Pediatría” (AEP / Spanish Association of Pediatrics). Its contents are elaborated mainly by members of the Grupo de Trabajo de Pediatría Basada en la Evidencia (Evidence Based Pediatrics Working Group). This group is part of both, the AEP and the “Asociación Española de Pediatría de Atención Primaria” (Spanish Association of Primary Care Pediatrics / AEPap).
Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-31.
Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464-8.
Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut. 1984;49:29-35.
Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de VB, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989-95.
Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703-7.
Albayrak D, Islek I, Kalayci AG, Gurses N. Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J Pediatr. 1994;125(6 Pt 1):1004-7.
Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol. 2002;24:540-4.
Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl-Roth K, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J Pediatr Hematol Oncol. 2003;25:797-800.
Carcao MD, Zipursky A, Butchart S, Leaker M, Blanchette VS. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl. 1998;424:71-4.
Duru F, Fisgin T, Yarali N, Kara A. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol. 2002;19:219-25.
El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol. 2006;115:46-52.
Erduran E, Aslan Y, Gedik Y, Orhan F. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr. 2003;45:295-300.
Fujisawa K, Iyori H, Ohkawa H, Konishi S, Bessho F, Shirahata A, et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol. 2000;72:376-83.
Ozsoylu S, Sayli TR, Ozturk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 1993;10:317-21.
Rosthoj S, Nielsen S, Pedersen FK. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group. Acta Paediatr. 1996;85:910-5.
Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006;148:489-94.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group. Arch Dis Child. 1992;67:1056-8.
De MD, Del PD, Del Vecchio GC, Jankovic M, Arrighini A, Giordano P, et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment.Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica. 2000;85:420-4.
[Protocol for the study and treatment of immune thrombocytopenic purpura. The Working Group of the Sociedad Espanola de Hematologia Pediatrica]. An Esp Pediatr. 1996;44:623-31.
Dickerhoff R, von RA. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr. 2000;137:629-32.
Iyori H, Bessho F, Ookawa H, Konishi S, Shirahata A, Miyazaki S, et al. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Japanese Study Group on childhood ITP. Ann Hematol. 2000;79:691-5.
Kuhne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122-5.
Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133:334-9.
Roganovic J, Letica-Crepulja M. Idiopathic thrombocytopenic purpura: a 15-year natural history study at the Children's Hospital Rijeka, Croatia. Pediatr Blood Cancer. 2006;47(5 Suppl):662-4.
Treutiger I, Rajantie J, Zeller B, Henter JI, Elinder G, Rosthoj S, et al. Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity? Arch Dis Child. 2007;92:704-7.
Perdikidis Olivieri L, Gonzalez de Dios J. El tratamiento precoz de la púrpura trombopénica idiopática no reduce la morbilidad y no parece tener impacto sobre la evolución a largo plazo de la misma. Evid Pediatr. 2007;3:98.
Premio MEDES 2012
Premio a la transparencia del SNS
Avalado por: Asociación Latinoamericana de Pediatría
Licencias Creative Commons
Estamos en: Cochrane Plus
Estamos en: Epistemonikos
Colaboramos con Pacientes Online
Una plataforma de: Lúa Ediciones 3.0
Adheridos a la iniciativa All Trials
The content in Evidencias en Pediatría is subject to Creative Commons Attribution Non Commercial No Derivatives 3.0 España